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Objectives: We analyzed the platelet proteome of circulating platelets during the onset of clopidogrel
therapy in patients with stable angina underwent percutaneous coronary intervention in order to investigate
the mechanisms that control platelet reactivity and clopidogrel response in this context.
Design & methods: Twenty patients were enrolled in this study. Blood samples were collected before
coronary angiography (T0), 12 h after 600 mg of clopidogrel (T1) and 24 h after percutaneous coronary
intervention (PCI) (T2). Platelet reactivity, Clopidogrel response and proteomic analysis were examined.
Results: Clopidogrel loading dose produced a signiﬁcant inhibition in all markers of platelet activation in
both ﬂow cytometry and aggregation tests. Among the proteins found differentially expressed, eighteen were
identiﬁed by MS/MS analysis and they resulted involved in the cytoskeleton rearrangement (proﬁlin-1,
calpain, α-soluble NSF attachment protein, thrombospondin), in the energetic metabolism (ubiquitin-like
modiﬁer-activating enzyme 1, protein-L-isoaspartate-(D-aspartate) O-methyltransferase and nucleoside
diphosphate kinase B) and in the oxidative stress (heat shock 70 kDa protein 5 and anti-stress induced
phosphoprotein 1.
Conclusions: The present study provides novel information on platelet proteome changes associated
with platelet activation and clopidogrel response. This investigation supports the development of further
proteomic studies for the identiﬁcation of novel platelet biomarkers.© 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.Introduction
Platelets are anucleate cells that play a primary role in physiologic
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ociety of Clinical Chemists. Publisheunactivated state, but in response to vascular injury platelets adhere
to the sub-endothelium, where their aggregation leads progressively
to the thrombus formation, restraining the hemorrhage.
Following vascular injury, as the endothelial damage caused by
coronary stenting, the plaque's highly prothrombotic contents is
exposed to the blood ﬂow, resulting in the adherence of platelets to
the damaged area, the release of activating agonists, stored in platelet
intracellular granules, that amplify the stimulation to the adjacent
platelets and the generation of a platelet-rich thrombus.
In order to prevent this acute manifestation, the use of antiplatelet
drugs showed clear beneﬁts over time, validated by several studies and
clinical trials [1]. The current guidelines, in fact, recommend the oral
administration of a dual antiplatelet therapy, with an ADP-receptor
antagonist like clopidogrel in association with aspirin [1]. Clopidogrel is
widely used as platelet inhibitor for coronary angioplasty procedures
especially in the setting of coronary stent implantation [2].
It is clear that undergoing to percutaneous coronary intervention
(PCI) with an adequate platelet inhibition level is associated with a
lower incidence of peri- and post-procedural adverse ischemic
complications compared to inadequate pre-treatment. Therefore a
loading dose of 600 mg of clopidogrel is now recommended as soond by Elsevier Inc. All rights reserved.
759E. Volpi et al. / Clinical Biochemistry 45 (2012) 758–765as possible before an urgent PCI and at least 6 h before an elective
procedure [1]. The high dose pre-treatment is generally associated
with an adequate and approximately homogeneous antiplatelet effect
[3,4], but the variability in platelet response and the mechanisms
connected with this phenomenon are still unclear. Traditional platelet
aggregation tests and the analysis of the platelet surface markers
using ﬂow cytometry continue to serve as remarkable tests for
platelet function studies [5]. Beside them, the use of proteomics holds
great promise for better understanding platelet biology and identi-
fying potential diagnostic markers and therapeutic targets.
The platelet proteome is altered in patients with coronary artery
diseases possibly because of the ongoing atherosclerotic process [6].
Recently, a high-resolution two-dimensional gel electrophoresis
(2DE)-based proteome analysis of platelets from non-ST segment
elevation acute coronary syndrome (NSTE-ACS) patients has been
performed, showing that proteomics can be used to follow platelet40.0
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Fig. 1. Panel A: Flow cytometric evaluation of platelet activation state and clopidogrel resp
administration of clopidogrel loading dose led to a signiﬁcant inhibition of all markers of plat
a. PAC-1 expression, indicated as percentage of positive events (mean±SD). b. P-selectin
phosphorylation, reported as Platelet Reactivity Index (mean±SD). Panel B: Clopidogrel inh
(after clopidogrel loading dose) and T2 (24 h after PCI). The mean platelet aggregation, ex
clopidogrel loading dose and the effect was protracted after the PCI.proteome changes during the follow-up [7]. The administration of
antiplatelet drugs and the stent placement are responsible for
multiple stimuli that may rapidly modify the expression of platelet-
related proteins. So we study the platelet proteome of patients
underwent clopidogrel treatment and elective PCI in order to
investigate the mechanisms that control platelet reactivity in this
context.
Materials and methods
Patients selection
Twenty patients with stable coronary artery disease were enrolled
in this study. The protocol was approved by the local ethical committee
and the informed consent was obtained from each subject before the
enrollment. All patients had received daily aspirin therapy of 100 mg0.0
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onse at T0 (baseline), T1 (after clopidogrel loading dose) and T2 (24 h after PCI). The
elet activation. The inhibitory effect on platelet activation was maintained after the PCI.
(CD62P) expression, indicated as percentage of positive events (mean±SD). c. VASP-
ibitory effect on ADP-induced (5 and 20μmol/L) platelet aggregation at T0 (baseline), T1
pressed as percentage of maximal aggregation, was inhibited by the administration of
Table 1
Patients demographics, medical history and concomitant medication.
Demographics
Age (yr) 68.4±7.7
Male sex (%) 75
BMI (kg/m2) 28.8±3.5
Medical history (%)
Hypertension 80
Hyperlipidemia 95
Diabetes mellitus 10
Smoking (current) 2
Family history of CAD 45
Concomitant medications (%)
ACE inhibitors 65
Sartans 25
β-blockers 70
Diuretics 35
Calcium channel blockers 25
Proton pump inhibitors 85
Statins 88
Target lesion coronary artery (%)
Left anterior descending 75
Left circumﬂex 20
Right 40
Stent implantation (%)
DES 80
BMS 20
[Data were expressed as mean±SD or %]
760 E. Volpi et al. / Clinical Biochemistry 45 (2012) 758–765for at least 1 month before the study. Exclusion criteria were acute
coronary syndrome or revascularization within the last 6 months;
concurrent ingestion of non-steroidal anti-inﬂammatory drugs (NSAID,
including COX-2 selective anti-inﬂammatory drugs), clopidogrel,
ticlopidine, dipyridamole or warfarin; platelet count outside the 100
to 450×109/L range; hematocritb25% or haemoglobinb100 g/L; and
chronic renal failure.
All patients were admitted in the Cardiology Department of the
Heart Hospital in Massa for symptomatic stable angina and investi-
gated with a diagnostic angiography to conﬁrm the necessity of
coronary revascularization. They received a 600 mg clopidogrel
loading dose ≥12 h before the PCI. After the procedure all patients
started the maintenance therapy with clopidogrel 75 mg/day for at
least 6 months and continued aspirin 100 mg/day indeﬁnitely.
Samples collection
Blood samples were drawn from an antecubital vein using a
19-gauge needle and the ﬁrst 2.5 mL were discarded. All samples
were collected in Vacutainer tubes (Becton Dickinson, San Jose, CA,
http://www.bdbiosciences.com) containing 3.8% sodium citrate as
anticoagulant. Patients' blood was drawn at three different time
points: before the PCI (T0), 12 h after the loading dose of clopidogrel
(T1) and 24 h after stenting (T2). Platelet-rich plasma (PRP) was
isolated by slow centrifugation at 22 °C at 100 g for 15 min. The
platelet pellet was then isolated by an additional centrifugation
at 1000 g for 20 min and stored at −80 °C until further protein
extraction.
Platelet activation markers: PAC-1 and CD62P
The determination of the platelet surface expression of αIIbβ3
integrin and P-selectin was performed by ﬂow cytometry. Whole
blood samples were diluted 1:6 in HEPES phosphate buffer (N-2-
hydroxy-ethyl-piperazine-N′-2-ethanesulfonic acid), containing ﬂuo-
rescein isothiocyanate (FITC) PAC-1 (Becton Dickinson, San Jose, CA,
http://www.bdbiosciences.com) or phycoerythrin (PE) conjugated
CD62P (Pharmingen, San Diego, CA, http://www.pharmingen.com)
monoclonal antibodies. Platelets were identiﬁed with the double
labeling method, using CD41a (FITC; Becton Dickinson, San Jose, CA)
or CD61 (PE; Pharmingen, San Diego, CA). Platelet activation was
induced with 5 μmol/L ADP (Sigma Chemical, St. Louis, MO, http://
www.sigmaaldrich.com). The unactivated (resting) samples were
used to establish the baseline expression of PAC-1 and CD62P on the
platelet surface. Each test was performed in parallel with the mouse
isotype control. All samples were incubated for 8 min at room
temperature (RT) in the dark and subsequently ﬁxed and diluted
1:10 with 1.0% ice-cold paraformaldehyde solution in PBS for analysis
by ﬂow cytometry (FACScan; Becton Dickinson, San Jose, CA, http://
www.bdbiosciences.com). PAC-1 and P-selectin expression levels
were calculated as percentage of positive events or relative ﬂuores-
cence intensity (RFI), expressed as linear ﬂuorescence channels
subtracted by the median value of the isotype-matched control
histogram.
Clopidogrel response
The platelet response to clopidogrel was evaluated through the
analysis of intraplatelet phosphorylation level of the Vasodilator-
stimulated phosphoprotein (VASP assay) by ﬂow cytometry and with
an aggregation test using optical aggregometry. The intraplatelet
VASP phosphorylation level reﬂects the P2Y12 receptor antagonism,
thus clopidogrel efﬁcacy. VASP phosporylation was measured by
whole blood ﬂow cytometry using PLT VASP/P2Y12 kit (Biocytex,
Marseille, France, http://www.biocytex.fr). The staining procedureand the calculation of the platelet reactivity index (PRI) were
performed according to the manufacturer's instructions.
Light transmittance aggregometry (LTA) has been the most widely
used technique to monitor the effects of antiplatelet agents. Platelet
aggregation was induced by adding ADP 5 and 20 μmol/L to 475 μL of
PRP in an aggregometer (Chrono-log Aggregometer, series 490;
Harveton, PA). Platelet aggregation was expressed as the maximum
percentage change in light transmittance, with platelet-poor plasma
used as a reference for 100% aggregation.
Protein extracts preparation
Pellets of platelets were resuspended in 350 μl of rehydration
solution (7 mol/L Urea, 2 mol/L thiourea, 4% 3-[(3-Cholamidopropyl)
dimethylammonio]-1-propanesulfonate (CHAPS), 60 mmol/L dithio-
threitol (DTT), 0.002% bromophenol blue), sonicated 4 times for 5 s
and incubated for 30 min at RT. After incubation the samples were
centrifuged for 10 min at 15,000 g to remove undissolved material.
Protein concentrations were measured with a RC-DC Protein Assay
from Bio-Rad, using bovine serum albumin as standard. The mean
value±SD of μg of proteins obtained for T0, T1 and T2 samples were
1502±353, 1563±416 and 1493±359 respectively.
2DE analysis
Isoelectrofocusing (IEF) was carried out by using 18 cm IPG-strips
(Immobiline Dry-Strips, GE Healthcare, UK, http://www.gehealthcare.
com) with a non-linear, pH 3–10, gradient. For analytical gels 150 μg
proteins were ﬁlled up to 350 μl with rehydration buffer supplemented
with 1% (v/v) pharmalytes, pH 3–10. 2DE was performed using the
Immobiline-polyacrylamide system as previously described [8]. For
preparative gels 1500 μg of proteins pooled from equal amounts of
samples were used. The analytical gels for all platelet protein samples
were processed in duplicate.
Staining and image analysis
Analytical gels were stained with ammoniacal silver nitrate as
previously described [9]. Preparative gels for mass spectrometric
analysis were stained with Coomassie Brilliant Blue G-colloidal [10].
761E. Volpi et al. / Clinical Biochemistry 45 (2012) 758–765The stained gels were scanned with an Epson Expression 1680 Pro
scanner and the images were analyzed with the Image-Master 2D
Platinum 6.01 (GE Healthcare, UK, http://www.gehealthcare.com)
software program. For the analysis the samples were grouped in three
different classes corresponding to T0, T1 and T2 time points. The
proteins with a ≥1.5-fold spot quantity change in each class were
selected and identiﬁed by MALDI TOF-TOF mass spectrometry.Maldi TOF-TOF acquisition, database searching and criteria for protein
identiﬁcation
Spots of interest were cut out from the master gel, treated and
analyzed as previously described [11]. Scaffold (version Scaffold_3_00_03,
Proteome Software Inc., Portland, OR) was used to validate MS/MS based
peptide and protein identiﬁcations. Peptide identiﬁcationswere accepted
if they could be established at greater than 95.0% probability as speciﬁed
by the Peptide Prophet algorithm [12]. Protein identiﬁcations were
accepted if they could be established at greater than 95.0% probability and
contained at least 2 identiﬁed peptides. Protein probabilities were
assigned by the Protein Prophet algorithm [13]. Proteins composed of5
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Fig. 2. Representative 2DE gel map of platelet proteins at T0 (A) T1 (B) and T2 (C) time point
12.5% SDS-PAGE. Proteins were detected by silver staining. The map was analyzed by Image
MS and refer to the number reported in Table 2.similar peptides and that could not be differentiated based on MS/MS
analysis alone were grouped to satisfy the principles of parsimony.
Western blot analysis
Alpha-soluble NSF attachment protein (α-SNAP), Stress induced
phosphoprotein 1 (STIP1) and Proﬁlin 1 were assessed by 1-D
Western blot (WB) analysis.
Amounts of the samples corresponding to 20 μg of proteins for α-
SNAP, 3 μg for STIP1, and 2.5 μg for Proﬁlin-1 were mixed with
Laemmli solution and heated 5 min at 100 °C. The samples were then
loaded on 12% polyacrylamide gels, electrotransferred to nitrocellu-
lose membranes and incubated with primary antibodies [11]. We
used as primary antibodies: rabbit polyclonal α-SNAP antibody
(1:500), rabbit polyclonal STIP1 (1:500) and rabbit polyclonal
Proﬁlin-1 (1:1000). For secondary antibody a goat anti-rabbit,
1:10,000 dilution, was used. For a negative control, the primary
antibody was omitted. Proteins were revealed with ECL detection
method. For each tested antibodies WB analysis was performed on all
platelets samples in duplicate. All primary antibodies were from
Abcam plc, UK, (http://abcam.com), secondary antibody was from10
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762 E. Volpi et al. / Clinical Biochemistry 45 (2012) 758–765Stressgen, MI (www.enzolifesciences.com). To visualize the different
expression of various products of proﬁlin-1, aliquots of 300 μg of
proteins were separated by 2DE using 3–10 non-linear strips 18 cm
before western blot analysis with speciﬁc antibody. For this
experiment the platelet samples appertaining to the same time
point (T0, T1 and T2), were pooled and processed in triplicate.
Statistical analysis
Data for continuous variables as the results of the platelet function
study were expressed as mean±standard deviation. Patients'
differences in platelet function at various time points (Figs. 1A and
B) were analyzed by the post hoc Scheffe's test after paired data
ANOVA. The optical density of the proteins was expressed as
percentage of the volume (mean±SD). The optical density of the
proteins was expressed as percentage of the volume (mean±SD).
The signiﬁcance of the differences for the proteomic study was
calculated using repeated measures Anova tests. pb0.05 were
considered to indicate statistical signiﬁcance.
Results
Patient's characteristics
A total of 20 consecutive patients who fulﬁlled the enrollment
criteria were prospectively included. Demographic, clinical and
angiographic characteristics of the studied population are summa-
rized in Table 1.
Platelet function study
On average, the administration of the clopidogrel loading dose
produced a signiﬁcant inhibition in all markers of platelet activation, as
demonstrated by the signiﬁcant differences observed between T0 and
T1 experimental time points, in both ﬂow cytometry tests [PAC-1
64.0±3.8 vs 57.9±7.9 p=0.0006; CD62P 48.7±6.2 vs 25.1±8.9
pb0.0001; PRI 81.4±3.5 vs 57.7±20.7 pb0.0001] and aggregation
tests [ADP 5 μmol/L 62.7±12.4 vs 40.6±11.2 pb0.0001; ADP
20 μmol/L 76.7±8.8 vs 53.9±12.0 pb0.0001], as reported in Figs. 1A
and B.
The treatment with proton pump inhibitors (PPI) did not
inﬂuence the clopidogrel response in our population, in fact there
was no signiﬁcant difference in platelet function results between
patients treated or not with PPI (p=ns).
In the samples collected after the PCI (T2) we observed that the
mean values of each platelet function test were comparable to those
obtained at T1 (p=ns, data not shown). These data indicate that the
revascularization procedure did not generate a re-activating re-
sponse, suggesting the efﬁcacy of the antiplatelet therapy in all
patients.
2DE platelet proteome and mass-spectrometry identiﬁcation of differentially
expressed proteins
Platelet protein extraction resulted in reproducible high-
resolution 2D gels. Silver staining of 2D gels grouped as time points,
showed similar protein patterns within a non-linear pH range from 3
to 10 with matching values over 80%. Typical 2D gel images of platelet
protein extracts from T0, T1 and T2 are shown in Figs. 2A, B, and C,
respectively. By computational 2D gel image comparison, a total of 24
protein spots were found to be differentially expressed, each
exhibiting ≥1.5 fold-change (either increase or decrease) of mean
value spot intensity (% of volume) among the three different time
points. Differentially expressed protein spots were subsequently
subjected to MS/MS analysis. Of the 24 spots, 75% were identiﬁed
by MS/MS spectrometry. A list of the eighteen identiﬁed proteins,
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expression level and p-values is shown in Table 2. In Fig. 3 the
selection of differentially expressed proteins is depicted on enlarged
gel images. Proteins identiﬁed by 2D/MS/MS proteomics were
classiﬁed into functional categories and were associated with
cytoskeleton, energetic metabolism, oxidative stress and inﬂamma-
tory response.
Validation of SNAP, STIP and Proﬁlin-1 by western blotting analysis
Western blot analysis with speciﬁc antibodies was used to validate
the expression changes of SNAP, STIP-1 and Proﬁlin-1 in platelet
samples at all three time points. All platelet samples were tested to
evaluate whether the observed protein expression changes were
conﬁrmed. A representative immunoblot for each protein tested is
shown in Fig. 4. For each tested protein the optical density of speciﬁc
immunoreactive band was determined and the resulting mean
values±SD were compared (T0, T1, T2) (Fig. 4, bar graphs). For
proﬁlin-1, we could not conﬁrm with 1D western blot the difference of
expression found by 2DE analysis (data not shown). So a 2DE blot was
performed and Fig. 4 shows the immunoblot of proﬁlin-1 obtained
after reaction with speciﬁc antibody demonstrating a different pattern
in the selected time points. The immunoreactive spots corresponded to
pI values ranging from 6.9 (spot 1) to 9 (spot 6). After statistical
analysis, except for spot 3 (pI 7.95), a signiﬁcant increase for all other
spots was detected at T1 when compared both with T0 and T2
conditions. The computation of theoretical pI value on the complete
sequence of proﬁlin-1 resulted 8.47, as calculated by UniProtKB/Swiss-
Prot service. This value corresponded to pI value of spot 5 for which wen° 10 Profilin-1
T0 T2T1
n° 19 Calpain
T0 T2T1
n° 25 Myosin 9
T0 T2T1
Fig. 3. Enlarged images of the 2D gels. Enlarged images of the 2DE gels highlighting the
isoaspartate(D-aspartate) O-methyltransferase for two representative gels for each time. Thdetected an increase of expression of 2.5 fold after clopidogrel
administration, that then disappeared after PCI.
Discussion
In the last decade the development and application of proteomics
have offered the opportunity to investigate the proteins involved in
the pathophysiology of several diseases. Recent studies have analyzed
the platelet proteome in resting condition, after various stimuli or as
subfractions (i.e. lysate, secretome) [14]. Furthermore platelets have
been studied in healthy volunteers and in patients affected by
coronary artery diseases [15], but the evaluation using a proteomic
approach of the platelet response during the onset of antiplatelet
therapy and the PCI is still unknown.
We analyzed the platelet proteome of 20 patients with stable
angina, who underwent elective PCI and stent placement. The results
from aggregation tests, the analysis of the platelet surface markers
with ﬂow cytometry and clopidogrel response were similar among
those patients. The identiﬁed protein changes, connected to the onset
of the clopidogrel therapy and the revascularization, showed an
increase in the energy metabolism enzymes and alterations in the
proteins associated with cytoskeleton-based processes, both of which
indicate platelet activation.
The activation of platelets by an agonist stimulates different
signal-transduction pathways that are initially mediated through
an increase in the intracellular calcium. The calcium-dependent
events include changes in the internal organization, the cytoskel-
eton rearrangement, the exocytosis of granule contents, the
production of thromboxane A2 and ﬁnally the activation ofn° 72 Annexin A5
T0 T2T1
n° 49 Protein-L-isoaspartate(D-
aspartate) O-methyltransferase
T0 T2T1
n° 75 SNAP
T0 T2T1
differential expression of proﬁlin-1, SNAP, calpain, annexin-5, myosin and protein-L-
e spots of interest are indicated by the arrows.
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Fig. 4. Validation of STIP-1, SNAP and Proﬁlin-1 different expression by immunoblot analysis. Conventional 1D-SDS gels were run with platelet protein extracts using 12% resolving
capacity. Amounts of the samples corresponding to 20 μg of proteins for SNAP, and 3 μg for STIP-1 were loaded into each lane for each sample. The western blot experiment is
representative of four samples appertaining to different times. Densitometry of the blots is shown under the graphs. Values that are signiﬁcantly different from T0 (** pb0.01,
***pb0.001) or T1 (##pb0.01, ###pb0.001) Anova tests. For proﬁlin-1 aliquots of 300 μg of proteins were separated by 2DE using 3–10 NL strips 18 cm before western blot analysis
with speciﬁc antibody. The image is representative of experiments performed in triplicate.
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of the calcium signal include protein kinase C, calpain, calmodulin,
phospholipase A2 and the annexins.
In this context, we interestingly observed that calpain, an intra-
cellular calcium dependent cysteine proteinase, was found only at T0,
before the antiplatelet treatment and the PCI. Calpain has been
localized in the cytoskeletal fraction of thrombin-stimulated platelets
and in points of attachment between cells and the extracellular matrix
[16]. Activation of calpain leads to a remodeling of the platelet
cytoskeleton and regulates the association of the cytoskeleton with
plasma membrane glycoproteins. In particular, the formation of
integrin-cytoskeletal signaling complexes is thought to be critical for
the phosphorylation of multiple cytoskeletal proteins and for the stable
incorporation of integrin αIIbβ3 into the contractile cytoskeleton [17].
Thus the elevated expression of calpain only at T0 supports the
evidence of a pathologic condition of platelet activation in patients
with CAD. This hyper-activation becomes successfully controlled by the
clopidogrel loading dose and after PCI.
Furthermore the different expression of other proteins like THBS-
1 fragment, α-SNAP and proﬁlin-1 may describe other mechanisms
involved in platelet reactivity in this context. THBS-1 is an adhesive
glycoprotein that mediates cell-to-cell and cell-to-matrix interac-
tions. It can bind ﬁbrinogen, ﬁbronectin, laminin, type V collagen and
integrins αVβ1, αVβ3 and αIIbβ3, thus the signiﬁcant reduction
observed at T1 well agrees with its function. In fact, THBS-1
expression decreased at T1 for the inhibitory effect of clopidogrel
loading dose on platelet reactivity, then after PCI it returned to be
similar to T0 presumably because the plaque rupture and the vasculardamage, induced by the stent deposition, may activate platelets and
increase THBS-1 expression.
Besides, a class of proteins termed SNAREs (including SNAP-23,
syntaxins) are involved in secretory granule/plasma membrane
fusion events, crucial mechanisms for the ampliﬁcation of platelet
response. SNAP proteins are expressed on the extracellular surface of
platelets [18] and speciﬁcally cleaved by calpain in activated cells
[19]. From our results, the increased amount of the α-SNAP at T1 may
suggest that platelets, and particularly their exocytosis process, have
been inhibited by clopidogrel loading dose.
Proﬁlins play a central role in the regulation of de novo actin
assembly by preventing spontaneous actin polymerization through the
binding of actin monomers, and adding monomeric actin to the actin-
ﬁlament ends [20,21]. Other cellular functions of proﬁlin in membrane
trafﬁcking and lipid based signaling have also been reported.
Phosphorylation of proﬁlin resulted in a signiﬁcant decrease in actin
polymerization, indicating an increased afﬁnity of phosphoproﬁlin
toward actin [22]. Our results suggest a change of proﬁlin-1 expression
proﬁle after clopidogrel administration with the appearance of
additional spots at T1. The acidic products (spot 1=pI 6.9 and spot
2=pI 7.2) might be imputable to post-transductional modiﬁcations
like phosphorylation or N-acetylation. On the other hand serine
phosphorylations N6-lysine (residues 103 and 106) and N-alanine
(residue 2) acetylations have been documented for proﬁlin-1 [23] and
a direct correlation of these post-transductional modiﬁcations with the
many functional effects of this protein has been reported [22,23].
In addition to these observations, the phosphorylation level of
proﬁlin and VASP appear to be modulated by clopidogrel. The
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frequently evaluated through the intracellular marker VASP-P and it
has been validated by clinical trials [24]. The interesting correlation
between VASP and proﬁlin suggests that platelet response, like the
activation of surface receptors like integrin αIIbβ3 mediated by VASP
and the cytoskeletal modiﬁcation mediated by proﬁlin, may be
inﬂuenced by balanced phosphorylating reactions. Thus VASP
phosphorylation and proﬁlin dephosphorylation represents the
inhibitory effect of clopidogrel on platelets.
Finally we observed that the expression of annexin-5 was evident
only at T1, after the clopidogrel loading dose. Annexin-5, a member of
the calcium-binding proteins annexins expressed in human platelet,
is a protein with potent and unique antithrombotic properties. The
antithrombotic effect exerted by annexin-5 seems to be mediated
mainly by mechanical shielding of phospholipids, thereby reducing
their availability for prothrombin binding and for the subsequent
coagulation reactions. Behan et al. [25] demonstrated that the effect
of clopidogrel results in an increased annexin-5 binding, assessed by
ﬂow cytometry, thus a suppression of platelet pro-coagulant re-
sponses through annexin-5 and our results support their ﬁnding with
the observation of an expression enhancement after clopidogrel
treatment.
In addition to the cytoskeleton-related protein, we detected
beta-arrestin 1, member of the arrestin family, which participates to
the P2Y receptors desensitization in platelets [26]. We interestingly
observed its expression only at T0, indicating that the hyper-
activation state of this ADP-dependent family of receptors became
subsequently regulated by the clopidogrel therapy.
We ﬁnally observed some interesting changes of expressions in
some groups of proteins, for example in those related to the energetic
metabolism, like ubiquitin-like modiﬁer-activating enzyme 1,
protein-L-isoaspartate-(D-aspartate) O-methyltransferase and nucle-
oside diphosphate kinase B. This effect may be addressed to the rapid
change of activating/inhibiting environment in which platelets were
isolated. The increasing expression of STIP-1 over time may be
ascribed to the endothelial damage provoked by the coronary
angiography and revascularization procedure.
Current limitations of the proteomic approach concern the difﬁculty
in the sample preparation in order to minimize the artifact, as in vitro
activation, and avoid any cell contamination. Therefore we selected our
platelet isolation method, using centrifugation and immediate freezing
storage, in order to minimize the sample processing procedures and to
maintain the platelets in their actual condition.Conclusion
Platelet reactivity is a complex process regulated by multiple
pathways and the interaction between those pathways and antiplatelet
drugs represents one of the most debated topic of the last few years in
cardiovascular research. We used a proteomic approach to reveal the
physiologic mechanisms connected with the platelet hyper-activation
and we found that the different expression of proteins associated with
cytoskeleton (proﬁlin-1, calpain, α-SNAP and THBS-1), energetic
metabolism (ubiquitin-like modiﬁer-activating enzyme 1, protein-L-
isoaspartate-(D-aspartate) O-methyltransferase and nucleoside di-
phosphate kinase B), oxidative stress (heat shock 70 kDa protein 5
and anti-stress induced phosphoprotein 1) and inﬂammatory response
may have a signiﬁcant impact in this context.Authors' disclosures or potential conﬂicts of interest
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